SubHero Banner

Opdivo® (nivolumab) and Yervoy® (ipilimumab) – Expanded indication

July 11, 2018 - Bristol-Myers Squibb announced the FDA approval of Opdivo (nivolumab) plus Yervoy (ipilimumab), for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Download PDF